- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Posterior segment.
Displaying page 1 of 3.
EudraCT Number: 2014-004042-96 | Sponsor Protocol Number: 32-009 | Start Date*: 2015-05-05 | |||||||||||
Sponsor Name:Santen Incorporated | |||||||||||||
Full Title: A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects with Non-Infectious Uveitis of the Posterior... | |||||||||||||
Medical condition: non -infectious Uveitis of the Posterior Segment of the Eye | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001589-15 | Sponsor Protocol Number: BLP 415-007 | Start Date*: 2005-09-15 | |||||||||||
Sponsor Name:Bausch & Lomb Incorporated | |||||||||||||
Full Title: A multi-center study evaluating the safety of a replacement intravitreal fluocinolone acetonide (FA) (0.59 mg) implant in patients with non-infectious posterior uveitis who were previously treated ... | |||||||||||||
Medical condition: Non-infectious Uveitis affecting posterior segment of the eye | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001622-29 | Sponsor Protocol Number: ALI-P01-21-006 | Start Date*: 2023-03-01 | |||||||||||
Sponsor Name:Alimera Sciences Europe Limited | |||||||||||||
Full Title: A NON-RANDOMISED, OPEN-LABEL, UNCONTROLLED, MULTI-CENTRE, PHASE IIIB STUDY EVALUATING THE SAFETY AND EFFICACY OF FLUOCINOLONE ACETONIDE 190 MICROGRAMS INTRAVITREAL IMPLANT IN PAEDIATRIC SUBJECTS FR... | |||||||||||||
Medical condition: Non-Infectious Uveitis affecting the posterior segment | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001595-19 | Sponsor Protocol Number: 32-007 | Start Date*: 2011-11-18 | |||||||||||
Sponsor Name:SANTEN INCORPORATED | |||||||||||||
Full Title: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infec... | |||||||||||||
Medical condition: Uveitis of the Posterior Segment of the Eye. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000736-26 | Sponsor Protocol Number: 206207-014 | Start Date*: 2006-05-17 |
Sponsor Name:Allergan Limited | ||
Full Title: An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX ... | ||
Medical condition: Non-infectious ocular inflammation of the posterior segment in intermediate or posterior uveitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) AT (Completed) IT (Completed) PT (Completed) BE (Completed) CZ (Completed) DE (Completed) GR (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019079-32 | Sponsor Protocol Number: 190342-033D | Start Date*: 2010-05-19 |
Sponsor Name:Allergan Limited | ||
Full Title: A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | ||
Medical condition: Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015509-38 | Sponsor Protocol Number: CAIN457C2302E1 | Start Date*: 2010-10-19 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppres... | |||||||||||||
Medical condition: Non-infectious, intermediate uveitis, posterior uveitis or panuveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000737-36 | Sponsor Protocol Number: 206207-015 | Start Date*: 2006-05-17 |
Sponsor Name:Allergan Limited | ||
Full Title: A 6-Week, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS... | ||
Medical condition: Non-infectious ocular inflammation of the anterior segment in anterior uveitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003661-17 | Sponsor Protocol Number: SS01 | Start Date*: 2012-11-09 | |||||||||||
Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust | |||||||||||||
Full Title: A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus PRN dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patie... | |||||||||||||
Medical condition: Diabetic macular oedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023779-24 | Sponsor Protocol Number: M10-1028 | Start Date*: 2010-12-06 |
Sponsor Name:Stichting Toegepast Caridologisch Onderzoek | ||
Full Title: A Comparison of Drug Eluting and Bare Metal Stents with Bivalirudin during PCI or Bivalirudin for 4 hours in Acute Coronary Syndromes. The Eindhoven Reperfusion Study | ||
Medical condition: Patients with ACS who are scheduled for primary PCI (STEMI) or for immediate PCI < 2.5 hours or early PCI < 48 hours (NSTEMI) and who are pre-treated with HLD clopidogrel | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003638-18 | Sponsor Protocol Number: 010906IN | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:SANTEN INCORPORATED | |||||||||||||
Full Title: LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 µg DE-109 for the Treatment of Active, Non-In... | |||||||||||||
Medical condition: Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014835-19 | Sponsor Protocol Number: CAIN457C2301 | Start Date*: 2010-02-15 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | ||||||||||||||||||||||||||||
Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de evaluar el AIN457 frente a pl... | ||||||||||||||||||||||||||||
Medical condition: Demostrar la eficacia y seguridad de AIN457 como terapia adyuvante en el tratamiento de la uveitis intermedia, uveitis posterior o panuveitis que precise inmunosupresión sistémica. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015508-24 | Sponsor Protocol Number: CAIN457C2301E1 | Start Date*: 2010-02-15 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | ||||||||||||||||||||||||||||
Full Title: Extensión de 38 semanas del Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de e... | ||||||||||||||||||||||||||||
Medical condition: Terapia adyuvante para el tratamiento de uveitis intermedia, uveitis posterior o panuveitis que precisen inmunosupresión sistémica | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014834-22 | Sponsor Protocol Number: CAIN457C2302 | Start Date*: 2010-07-06 | |||||||||||||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||||||||||||
Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la induc... | |||||||||||||||||||||||
Medical condition: determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la inducción y mantenimiento de la supresión de la uveítis en adultos con uveítis activa no infecciosa inter... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-018919-16 | Sponsor Protocol Number: TG-MV-010 | Start Date*: 2010-06-28 | |||||||||||
Sponsor Name:ThromboGenics NV | |||||||||||||
Full Title: An Open-Label, Ascending- Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects... | |||||||||||||
Medical condition: Patients who require primary pars plana vitrectomy. A sample of vitreous will be taken at beginning of surgery for PK analysis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002708-25 | Sponsor Protocol Number: RIVAROXACS3001 (BAY59-7939/13194) | Start Date*: 2008-11-27 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome The ATLAS ACS 2 ... | |||||||||||||
Medical condition: Acute Coronary Syndrome (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) LT (Completed) DE (Completed) PT (Completed) SK (Completed) HU (Completed) FR (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) IT (Completed) LV (Completed) CZ (Completed) BG (Completed) BE (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001810-14 | Sponsor Protocol Number: PSV-FAI-001 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:pSivida Corporation | |||||||||||||
Full Title: A PHASE III, MULTI-NATIONAL, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A FLUOCINOLONE ACETONIDE INTRAVITREAL (FAI) INSERT IN SUBJECTS WITH CHRONIC NON-INFECTIOUS... | |||||||||||||
Medical condition: chronic non-infectious uveitis affecting the posterior segment of the eye | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022128-63 | Sponsor Protocol Number: LX211-11 | Start Date*: 2011-03-16 |
Sponsor Name:Lux Biosciences, Inc. | ||
Full Title: A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Non-Infectious Uveitis Involving the Inte... | ||
Medical condition: Non-Infectious Intermediate, Posterior or Pan-uveitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) IT (Completed) GB (Completed) NL (Ongoing) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015586-31 | Sponsor Protocol Number: 190342-031D | Start Date*: 2010-01-29 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug ... | |||||||||||||
Medical condition: Rhegmatogenous Macula-off Retinal Detachment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002642-23 | Sponsor Protocol Number: NVD-CLN01 | Start Date*: 2016-11-28 |
Sponsor Name:Novadip Biosciences | ||
Full Title: A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by inte... | ||
Medical condition: Patients diagnosed with symptomatic degenerative spondylolisthesis grade I or II with an indication for spinal fusion of one vertebral segment (L1-S1). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) PL (Completed) CZ (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
